Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
TerveystaloFRA:4TS +3.10%73 3-Year EBITDA Growth Rate is 17.50% as of Jun. 2026, which is at its 10-year median of 17.50. GuruFocus rates FRA:4TS with a GF Score™ of 73/100 and a GF Value™ of €8.61 (Modestly Undervalued). The stock has 5 warning signs investors should review. Among 526 Healthcare Providers & Services companies, Terveystalo ranks better than 62.93% on this metric.
During the past 12 months, Terveystalo's average EBITDA Per Share Growth Rate was -11.50% per year.
During the past 3 years, the average EBITDA Per Share Growth Rate was 17.50% per year.
During the past 5 years, the average EBITDA Per Share Growth Rate was 5.20% per year.
During the past 10 years, the average EBITDA Per Share Growth Rate was 12.00% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.
During the past 12 years, the highest 3-Year average EBITDA Per Share Growth Rate of Terveystalo was 35.30% per year. The lowest was -16.70% per year. And the median was 17.50% per year.
EBITDA per Share is the amount of Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) per outstanding share of the company's stock.
Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) is what the company earns before it expenses interest, taxes, depreciation and amortization.
Terveystalo 3-Year EBITDA Growth Rate Related Terms
FRA:4TS vs HCA, THC, EHC: 3-Year EBITDA Growth Rate Comparison
For the Medical Care Facilities subindustry, Terveystalo's 3-Year EBITDA Growth Rate, along with its competitors' market caps and 3-Year EBITDA Growth Rate data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Terveystalo 3-Year EBITDA Growth Rate vs Healthcare Providers & Services Industry
For the Healthcare Providers & Services industry and Healthcare sector, Terveystalo's 3-Year EBITDA Growth Rate distribution charts can be found below:
* The bar in red indicates where Terveystalo's 3-Year EBITDA Growth Rate falls into.
This is the 3-year average growth rate of EBITDA per Share. The growth rate is calculated using exponential compounding based on the latest four year annual data.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.
What does a 3-Year EBITDA Growth Rate of 17.50% mean?
Terveystalo (FRA:4TS) has a 3-Year EBITDA Growth Rate of 17.50% as of Jun. 2026. 3-Year EBITDA Growth Rate is the 3-year average growth rate of EBITDA per share. View historical data for Terveystalo and its competitors. This is near median its historical median of 17.50. According to the industry distribution chart, Terveystalo ranks #195 out of 526 companies in the Healthcare Providers & Services industry, placing it in the top 37.1%.
Is Terveystalo's 3-Year EBITDA Growth Rate too high?
Terveystalo's current 3-Year EBITDA Growth Rate of 17.50% is near median its 10-year median of 17.50. The Healthcare Providers & Services industry median 3-Year EBITDA Growth Rate is 9.90. Terveystalo's value of 17.50% is 76.8% above this industry median. Based on the distribution chart, Terveystalo ranks #195 out of 526 companies in the Healthcare Providers & Services industry, which is above the industry midpoint. Overall, Terveystalo has a GF Score™ of 73/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Terveystalo's 3-Year EBITDA Growth Rate compare to HCA and THC?
According to the Healthcare Providers & Services industry distribution chart, Terveystalo ranks #195 out of 526 companies for 3-Year EBITDA Growth Rate. This puts Terveystalo in the upper half of its industry. The industry median 3-Year EBITDA Growth Rate is 9.90. Terveystalo's value of 17.50% is 76.8% above this benchmark. While the company's 10-year median is 17.50 vs. the industry median of 9.90, Terveystalo has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year EBITDA Growth Rate for a Healthcare Providers & Services company?
The median 3-Year EBITDA Growth Rate among Healthcare Providers & Services companies is 9.90, based on 526 companies in the industry. Companies in the top quartile (top 25%) have a 3-Year EBITDA Growth Rate significantly above this median, while those in the bottom quartile fall well below. However, 3-Year EBITDA Growth Rate should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Terveystalo's current 3-Year EBITDA Growth Rate of 17.50% is 76.8% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year EBITDA Growth Rate mean?
A high 3-Year EBITDA Growth Rate can signal that a stock is expensive relative to its fundamentals. 3-Year EBITDA Growth Rate is the 3-year average growth rate of EBITDA per share. View historical data for Terveystalo and its competitors. For the Healthcare Providers & Services industry, the median 3-Year EBITDA Growth Rate is 9.90 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Terveystalo's current 3-Year EBITDA Growth Rate is 17.50%, which is near median its own 10-year median of 17.50. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Terveystalo stock overvalued right now?
Based on GuruFocus' analysis, Terveystalo (FRA:4TS) is currently considered Modestly Undervalued. The stock's GF Value™ is €8.61, compared to a current price of €7.65 — trading 11.1% below its estimated fair value. The current 3-Year EBITDA Growth Rate is 17.50%, which is near median its 10-year median of 17.50 and 76.8% above the Healthcare Providers & Services industry median of 9.90. Terveystalo's overall GF Score™ is 73/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year EBITDA Growth Rate calculated?
3-Year EBITDA Growth Rate is calculated from a company's financial statements. For Terveystalo (FRA:4TS), the current 3-Year EBITDA Growth Rate is 17.50% as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Terveystalo (FRA:4TS) Overvalued in 2026?
Based on GuruFocus' analysis, Terveystalo stock appears to be undervalued.
The current stock price of €7.65 is trading 11.1% below its estimated GF Value™ of €8.61.
GuruFocus considers Terveystalo to be Modestly Undervalued.
Key valuation signals for FRA:4TS:
3-Year EBITDA Growth Rate: 17.50% (near median its 10-year median of 17.50)
GF Value™: €8.61 vs. price of €7.65 (11.1% below fair value)
Industry Position: 76.8% above the Healthcare Providers & Services median (#195 of 526)
No single metric tells the full story. See the FRA:4TS stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Terveystalo PLC o is a healthcare service provider in Finland. The company offers primary and specialized healthcare services to corporate, private, and public sector customers. The healthcare service offering of the company includes general practice and specialist medical care, diagnostic services, outpatient surgery, dental services and other adjacent services; it covers the entire integrated treatment chain of healthcare. The Group comprises of three reporting segments: Healthcare Services, Portfolio Businesses, and Sweden, out of which it derives maximum revenue from Healthcare Services segment.
73GF Score
Get the complete analysis for FRA:4TS
3-Year EBITDA Growth Rate is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:4TS has been successfully added to your 
